Seagen wins Enhertu patent dispute with Daiichi Sankyo

A US jury has decided that Daiichi Sankyo and AstraZeneca's breast cancer drug Enhertu infringes a patent held by US biotech Seagen, awarding almost $42 million in damages.

AZ pays $775m to settle patent dispute with Chugai over Ulto...

AstraZeneca has resolved a lingering liability following its takeover of Alexion with an agreement to pay $775 million to settle a patent dispute with Chugai Pharma, Roche's Japanese subsid

Alnylam sues Pfizer, Moderna over COVID-19 vaccines

Alnylam claims it is owed a slice of the massive revenues booked by Pfizer and Moderna for their mRNA-based COVID-19 vaccines, because they are both infringing patents its holds on a delive

ViiV claims $1.25bn settlement from Gilead in HIV patent dis...

A patent dispute between ViiV Healthcare and Gilead Sciences has been resolved, with Gilead agreeing to pay a $1.25 billion settlement as well as royalties on sales of one of its top HIV pr

Novartis blocks generic to MS blockbuster Gilenya in US pate...

Novartis has blocked an attempt by Chinese drugmaker HEC Pharma to launch a generic version of its big-selling multiple sclerosis drug Gilenya in the US for almost six years.

Gilead will challenge US government patent on PrEP drug Truv...